A5062633357- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Lung Cancer Treatments and Mutations
- CNS Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Immunodeficiency and Autoimmune Disorders
- Breast Implant and Reconstruction
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Acute Lymphoblastic Leukemia research
- Cancer Treatment and Pharmacology
- Venous Thromboembolism Diagnosis and Management
- Gastric Cancer Management and Outcomes
- Cutaneous lymphoproliferative disorders research
- Multiple and Secondary Primary Cancers
- Ovarian cancer diagnosis and treatment
- Breast Lesions and Carcinomas
- Eosinophilic Disorders and Syndromes
- Abdominal Trauma and Injuries
- Chronic Myeloid Leukemia Treatments
- Education Systems and Policy
- Lymphatic System and Diseases
University Hospitals of Leicester NHS Trust
2016-2025
University of Leicester
2010-2024
National Health Service
2021
Leicester Royal Infirmary
2002-2017
MRC Toxicology Unit
2010-2011
Medical Research Council
2010-2011
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors immunoarchitectural patterns (IAPs) for all stages pediatric adult patients with NLPHL.
Summary Chronic lymphocytic leukaemia ( CLL ) cells encounter T ‐cells and proliferate in response to ‐cell signals the lymph node microenvironment. In this report we determined interleukin 21 IL 21) function showed that 4 4) act co‐operatively promote leukaemic cell proliferation without apoptosis or differentiation We further show increased side population SP cells, which are associated with resistance chemotherapy self‐renewal capacity . major cytokines produced by recently described CD +...
Delayed lymphocyte and T-cell immune reconstitution following bendamustine-rituximab (BR) for indolent non-Hodgkin lymphoma (iNHL) has been described, but no information is available chronic lymphocytic leukaemia (CLL). We present a population-based retrospective analysis of risk infection BR. Outcomes included timing/correlates CD4+ recovery ≥grade 3 infections. Consecutively treated patients (1 April 2014 to 31 January 2017) were (n = 295),with median age 65 years (range 33-92); 57% 1st...
Abstract High-dose methotrexate (HD-MTX) is increasingly used as prophylaxis for patients with diffuse large B-cell lymphoma (DLBCL) at high risk of central nervous system (CNS) relapse. However, there limited evidence to guide whether intercalate HD-MTX (i-HD-MTX) between R-CHOP-21 (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone given 21-day intervals) or give it the end treatment (EOT) R-CHOP-21. We conducted a retrospective, multicenter analysis 334 DLBCL who...
The "hidden curriculum" in medical school includes a stressful work environment, un-empathic role models, and prioritisation of biomedical knowledge. It can provoke anxiety cause students to adapt by becoming cynical, distanced less empathic. Lower empathy, turn, has been shown harm patients as well practitioners. Fortunately, evidence-based interventions counteract the empathy dampening effects hidden curriculum. These include early exposure real patients, providing with real-world...
Summary Approximately 70% of chronic lymphocytic leukaemia (CLL) patients present with early stage disease, therefore defining which will progress and require treatment is a major clinical challenge. Here, we the largest study prognostic markers ever carried out in Binet A ( n = 1154) median follow‐up 8 years. We assessed impact lymphocyte doubling time (LDT), immunoglobulin gene IGHV ) mutation status, CD38 expression, ZAP‐70 expression fluorescence situ hybridization (FISH) cytogenetics...
Abstract During the COVID-19 pandemic, ibrutinib with or without rituximab was approved in England for initial treatment of mantle cell lymphoma (MCL) instead immunochemotherapy. Because limited data are available this setting, we conducted an observational cohort study evaluating safety and efficacy. Adults receiving untreated MCL were evaluated toxicity, response, survival, including outcomes high-risk (TP53 mutation/deletion/p53 overexpression, blastoid/pleomorphic, Ki67 ≥ 30%). A total...
Introduction: Classical Hodgkin Lymphoma (cHL) is frequently accompanied by the 9p24.1 amplicon, which contains PD-L1 and PD-L2 immune checkpoint genes results in their overexpression. Blockade of PD-1/PD-L1 PD-1/PD-L2 interactions with anti–PD-1 antibodies clinically effective; however, it has not been established if blockade interaction alone sufficient for therapeutic effect. Avelumab a fully human IgG1 monoclonal antibody that selectively binds to PD-L1, leaving intact, thus enabling...
Abstract The 9p24.1 chromosomal alteration in classical Hodgkin lymphoma (cHL) is associated with increased expression of programmed death ligand 1 (PD-L1)/PD-L2 and an immunosuppressive tumor microenvironment. Blockade PD-L1/PD-1 interactions avelumab (anti–PD-L1) hypothesized to restore antitumor immunity. JAVELIN Hodgkins was a phase 1b, multiple-dose, open-label, randomized, parallel-arm trial patients relapsed/refractory (R/R) cHL. Primary end points included target occupancy by...
Summary Standard treatment for classical Hodgkin lymphoma (cHL) is poorly tolerated in older patients and results disappointing. We assessed safety efficacy of brentuximab vedotin (BV), previously untreated with cHL unfit standard due to age, frailty or comorbidity. The primary outcome was complete metabolic response (CMR) by positron emission tomography/computed tomography after four BV cycles (PET4). secondary outcomes included progression‐free survival (PFS), overall (OS), toxicity. In...
Summary Traditionally, patients with asymptomatic, advanced‐stage follicular lymphoma were managed a watchful‐waiting approach until disease progression. The ‘Watch and Wait’ Phase‐3 randomised international trial examined whether rituximab could delay the need for treatment effect on quality of life (QoL). In this article, we present long‐term results QoL aspect trial. Patients to (Arm A), induction B) or followed by maintenance C). We outcomes from 180 188 C) an exploratory analysis 82...
Summary Relapsed or refractory classical Hodgkin lymphoma ( cHL ) is associated with a poor outcome when standard chemotherapy fails. Brentuximab vedotin BV an anti‐ CD 30 monoclonal antibody‐drug conjugate licensed for use at relapse after autologous stem cell transplant ASCT following two prior therapies in those unsuitable . There are limited data assessing the ability of to enable curative SCT We performed UK ‐wide retrospective study 99 ‐naïve relapsed/refractory All had received 2...
Bendamustine is among the most effective chemotherapeutics for indolent B-cell non-Hodgkin lymphomas (iNHL), but trial reports of significant toxicity, including opportunistic infections and excess deaths, led to prescriber warnings. We conducted a multicenter observational study evaluating bendamustine toxicity in real-world practice. Patients receiving at least 1 dose with/without rituximab (R) iNHL were included. Demographics, lymphoma treatment details, grade 3 5 adverse events (AEs)...
Figure 1.(a) Sequencing trace showing the NOTCH1 mutation c.7544_7545delCT (RefSeq NM_017617.2);arrows point to position of nucleotide change.(b-e) show abnormal blood parameters observed on completion infusion.